Market Place
Sourcing Support
Everest Medicines To Unveil 2025 Financials On March 26, 2026
16 Mar 2026 //
PR NEWSWIRE
Everest Pharma To Report 2025 Financials On March 26, 2026
10 Mar 2026 //
PR NEWSWIRE
Everest Medicines To Present At J.P. Morgan Healthcare Conference
05 Jan 2026 //
PR NEWSWIRE
Everest Enrolls 1st Patient In Global Ph1 Trial for EVM14 Vaccine
15 Oct 2025 //
PHARMIWEB
Everest Medicines Publish Etrasimod`s Phase III ENLIGHT UC Study
09 Oct 2025 //
PHARMIWEB
Everest Medicines Reveals First-Half 2025 Interim Results
28 Aug 2025 //
PR NEWSWIRE
Everest Medicines Expands Strategic Investment in I-MAB
01 Aug 2025 //
PR NEWSWIRE
Everest Medicines Advances AI-Powered mRNA Platform at R&D Day
08 Jul 2025 //
INDPHARMAPOST
Everest Medicines: FDA Clears IND for Tumor Antigen Vaccine EVM14
25 Mar 2025 //
PR NEWSWIRE
Everest Medicines Doses First Patient with EVM16 Cancer Vaccine
06 Mar 2025 //
PR NEWSWIRE
Everest Medicines Hosts Investor Calls On mRNA Vaccine Programs
28 Feb 2025 //
PR NEWSWIRE
Everest Medicines Initiates IIT For mRNA Cancer Vaccine EVM16
22 Aug 2024 //
BIOSPACE
Everest Medicines Announces Financial Results for Full Year 2023
27 Mar 2024 //
PR NEWSWIRE
Singapore gives nod to China-based Everest Medicines` drug for nephropathy
20 Mar 2024 //
BIOSPECTRUM ASIA
Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN
19 Mar 2024 //
PR NEWSWIRE
Everest Medicines Announces Revenue Expected to be Between RMB124M & RMB126M
21 Jan 2024 //
PR NEWSWIRE
Everest Medicines Announces New Drug Application Acceptance of Nefecon
26 Dec 2023 //
PR NEWSWIRE
Everest Medicines Announces China NMPA`s Approval of Nefecon
23 Nov 2023 //
PR NEWSWIRE
Everest Medicines Announces New Drug Application Approval for Nefecon
27 Oct 2023 //
PR NEWSWIRE
Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon
26 Oct 2023 //
PR NEWSWIRE
Everest Medicines Announces Approval of XERAVA® in Taiwan
27 Sep 2023 //
PR NEWSWIRE
Kezar and Everest Medicines Enter into an Agreement to Develop Zetomipzomib
20 Sep 2023 //
BUSINESSWIRE
Everest Announces NMPA Recommends Priority Review for Cefepime-Taniborbactam
19 Sep 2023 //
PR NEWSWIRE
Everest Medicines Announces NDA Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon
24 Aug 2023 //
PR NEWSWIRE
Everest Medicines Announces Interim Results for First Half of 2023
23 Aug 2023 //
PR NEWSWIRE
Everest Medicines to Announce First Half 2023 Financial Results
08 Aug 2023 //
PR NEWSWIRE
Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study
31 Jul 2023 //
PR NEWSWIRE
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA
26 Jul 2023 //
PR NEWSWIRE
Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer
15 Jun 2023 //
PR NEWSWIRE
Everest Medicines Announces Completion in Ph 3 Trial of Etrasimod in Asia
16 May 2023 //
PR NEWSWIRE
China marks beginning of new treatment for primary immunoglobulin A nephropathy
24 Apr 2023 //
BIOSPECTRUM ASIA
Everest Medicines Launches Nefecon in China`s Hainan Boao Pilot Zone
23 Apr 2023 //
PR NEWSWIRE
Everest Medicines Announces NDA Acceptance for Nefecon
05 Apr 2023 //
PR NEWSWIRE
Everest Announces Financial Results for Full Year Ended December 31, 2022
30 Mar 2023 //
PR NEWSWIRE
Everest Receives Upfront Payment from Gilead for Trodelvy-Related Transaction
26 Mar 2023 //
PR NEWSWIRE
Everest Medicines Announces Approval of Xerava in China
17 Mar 2023 //
PR NEWSWIRE
Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023
15 Mar 2023 //
PR NEWSWIRE
Everest debuts $130M mRNA vaccine plant in China
02 Mar 2023 //
FIERCE PHARMA
Everest Announces South Korea Grants Fast Track Review Designation to Nefecon
09 Feb 2023 //
PR NEWSWIRE
Everest Medicines Announces Top-line Data from Phase I Study of EVER206
17 Jan 2023 //
PR NEWSWIRE
Everest Medicines Announces New Strategic Plans, Reinforcing Transformation
03 Jan 2023 //
PR NEWSWIRE
